Orphan designation for SYD003 for the treatment of pancreatic cancer. Granted by the European Medicines Agency (EMA) on 22 August 2014 and by the US Food and Drug Administration (FDA) on 20 October 2014.
Orphan designation for pancreatic cancer
Orphan designation for SYD003 for the treatment of pancreatic cancer. Granted by the European Medicines Agency (EMA) on 22 August 2014 and by the US Food and Drug Administration (FDA) on 20 October 2014.